Reports Q4 revenue $12.8M, consensus $14.4M. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is being recognized as an important treatment option for women with postpartum depression and we believe it will continue to be instrumental in accelerating progress in maternal mental health,” said Barry Greene, CEO. “In 2025, our focus will remain on helping more women with postpartum depression receive treatment with ZURZUVAE, advancing our focused R&D efforts, and creating near and long-term value for Sage and its shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- SAGE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Sage Therapeutics price target raised to $9 from $6 at Mizuho
- Sage Rejects Biogen Bid but Could be Open to Other Offers
- M&A News: Sage Rejects Biogen’s $469M Takeover Bid over Valuation Concerns
- China’s DeepSeek sinks tech, AT&T reports Q4 beat: Morning Buzz